| Not Yet Recruiting | Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma NCT07110233 | University of California, San Francisco | N/A |
| Not Yet Recruiting | A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune NCT07368023 | Ningbo Medical Center Lihuili Hospital | — |
| Not Yet Recruiting | Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thromb NCT07122089 | Center Eugene Marquis | Phase 2 |
| Not Yet Recruiting | Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy NCT07192848 | Song Peng | Phase 2 |
| Not Yet Recruiting | Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinom NCT04996914 | RWTH Aachen University | N/A |
| Recruiting | Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC NCT06904196 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Recruiting | Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT NCT06904183 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Not Yet Recruiting | A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary NCT06779461 | InnoBM Pharmaceuticals Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004) NCT06643533 | Fujian Provincial Hospital | — |
| Recruiting | Y-90 SIRT for Unresectable HCC Larger Than 7cm NCT06707233 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Enrolling By Invitation | Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China NCT06712017 | GrandPharma (China) Co., Ltd. | — |
| Recruiting | Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) NCT06561399 | Fujian Provincial Hospital | — |
| Recruiting | Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT NCT06492395 | Second Affiliated Hospital of Guangzhou Medical University | Phase 3 |
| Not Yet Recruiting | A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior NCT06535737 | Chulalongkorn University | Phase 2 |
| Active Not Recruiting | Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellul NCT05901194 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Recruiting | DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC NCT06397235 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Recruiting | Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC NCT06397222 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Recruiting | Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. NCT06375486 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC NCT05911633 | Terumo Europe N.V. | N/A |
| Recruiting | mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Crite NCT06607107 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Suspended | Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2) NCT05797870 | Center Eugene Marquis | Phase 2 |
| Recruiting | Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma NCT06187961 | Tongji Hospital | Phase 2 |
| Recruiting | Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma NCT06133062 | Chang Gung Memorial Hospital | Phase 2 |
| Active Not Recruiting | Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) NCT05953337 | ABK Biomedical | N/A |
| Recruiting | Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05985798 | Second Affiliated Hospital of Guangzhou Medical University | Phase 3 |
| Unknown | Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepa NCT06040177 | First Affiliated Hospital of Guangxi Medical University | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-w NCT05638438 | Zhujiang Hospital | — |
| Recruiting | Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC NCT05608213 | Second Affiliated Hospital of Guangzhou Medical University | Phase 3 |
| Recruiting | Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05608200 | Second Affiliated Hospital of Guangzhou Medical University | Phase 3 |
| Recruiting | Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Inv NCT05992220 | Asan Medical Center | Phase 2 |
| Terminated | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types K NCT05497453 | Omega Therapeutics | Phase 1 / Phase 2 |
| Unknown | Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT NCT05530785 | Yongchang Zhang | N/A |
| Completed | SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC NCT06916546 | Second Affiliated Hospital of Guangzhou Medical University | — |
| Recruiting | Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma NCT04965454 | Queen's Medical Center | Phase 2 |
| Unknown | Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcin NCT05114148 | UMC Utrecht | N/A |
| Recruiting | Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma NCT05717738 | Tongji Hospital | — |
| Completed | Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC NCT04926376 | ABK Biomedical | N/A |
| Unknown | Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma NCT05031949 | Zhang Bi Xiang, MD | Phase 1 |
| Unknown | Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined Wit NCT05057104 | Beijing 302 Hospital | — |
| Unknown | DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC NCT04967482 | Second Affiliated Hospital of Guangzhou Medical University | N/A |
| Unknown | TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT NCT04967495 | Second Affiliated Hospital of Guangzhou Medical University | N/A |
| Unknown | Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolizati NCT05390112 | University Hospital, Rouen | — |
| Unknown | Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC NCT04718909 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Recruiting | Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC NCT04522544 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Completed | Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment NCT04511455 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Recruiting | TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors NCT06487663 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Completed | TACE Combined With Lenvatinib and Sintilimab for Advanced HCC NCT04599790 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Completed | TACE Combined With Sorafenib and Tislelizumab for Advanced HCC NCT04599777 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Completed | The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein NCT04997850 | Xinrui Zhu，MD | Phase 1 / Phase 2 |
| Unknown | TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC NCT04592029 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Recruiting | Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizuma NCT04224636 | Ludwig-Maximilians - University of Munich | Phase 2 |
| Recruiting | Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma NCT05713994 | Ze-yang Ding, MD | — |
| Unknown | PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC NCT04273100 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Completed | Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With o NCT06408753 | The University of Hong Kong | — |
| Completed | Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT NCT06265883 | Second Affiliated Hospital of Guangzhou Medical University | — |
| Unknown | Thermal Ablation Followed by Immunotherapy for HCC NCT03864211 | Xiangya Hospital of Central South University | Phase 1 / Phase 2 |
| Unknown | Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma NCT03881501 | Huazhong University of Science and Technology | — |
| Unknown | Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma NCT03807947 | Humanitas Clinical and Research Center | N/A |
| Unknown | Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) NCT05543304 | First Affiliated Hospital of Wenzhou Medical University | — |
| Unknown | The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma NCT03652467 | Jinan Military General Hospital | Phase 1 |
| Withdrawn | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine NCT03563170 | ImmunityBio, Inc. | Phase 1 / Phase 2 |
| Unknown | Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge NCT03277716 | Fan Weijun | N/A |
| Completed | Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma NCT03533920 | Jeil Pharmaceutical Co., Ltd. | N/A |
| Unknown | Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Tai NCT03283956 | National Taiwan University Hospital | — |
| Completed | HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients NCT03379844 | UMC Utrecht | Phase 2 |
| Completed | Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma NCT03138031 | The National Ribat University | N/A |
| Completed | Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma NCT03564405 | Jeil Pharmaceutical Co., Ltd. | N/A |
| Completed | A Study to Evaluate SHR-1210 in Subjects With Advanced HCC NCT02989922 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Unknown | Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC NCT02967887 | CbsBioscience | Phase 2 |
| Completed | Stereotactic Body Radiotherapy Based Treatment for Hepatocellular Carcinoma With Extensive Portal Vein Tumor T NCT04966195 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Terminated | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) NCT01009593 | Abbott | Phase 3 |